Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2018, Article ID 3015854, 10 pages
https://doi.org/10.1155/2018/3015854
Clinical Study

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study

1Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
2Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, China
3Department of Endocrinology and Metabolism, The Second People’s Hospital of Kashi, Xinjiang Uygur Autonomous Region 844000, China
4Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China

Correspondence should be addressed to Xiaoyun Cao; moc.361@4952nuyoaixoac and Zhaoyun Zhang; nc.ude.naduf@gnahznuyoahz

Received 13 July 2017; Accepted 13 December 2017; Published 26 April 2018

Academic Editor: Mario Maggi

Copyright © 2018 Ming Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. M. Dekkers, N. R. Biermasz, A. M. Pereira, J. A. Romijn, and J. P. Vandenbroucke, “Mortality in acromegaly: a metaanalysis,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 1, pp. 61–67, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Jadresic, L. M. Banks, D. F. Child et al., “The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours,” QJM: An International Journal of Medicine, vol. 51, no. 202, pp. 189–204, 1982. View at Google Scholar
  3. A. Colao, D. Ferone, P. Marzullo, and G. Lombardi, “Systemic complications of acromegaly: epidemiology, pathogenesis, and management,” Endocrine Reviews, vol. 25, no. 1, pp. 102–152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. D. R. Clemmons, “Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly,” Pituitary, vol. 5, no. 3, pp. 181–183, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Giustina, P. Chanson, M. D. Bronstein et al., “A consensus on criteria for cure of acromegaly,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 7, pp. 3141–3148, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. L. B. Barnard, W. G. Grantham, P. Lamberton, T. M. O'Dorisio, and I. M. Jackson, “Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995),” Annals of Internal Medicine, vol. 105, no. 6, pp. 856–861, 1986. View at Publisher · View at Google Scholar
  7. S. W. J. Lamberts, M. Zweens, L. Verschoor, and E. D. Pozo, “A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs,” The Journal of Clinical Endocrinology & Metabolism, vol. 63, no. 1, pp. 16–19, 1986. View at Publisher · View at Google Scholar · View at Scopus
  8. L. M. Sandler, J. M. Burrin, G. Williams, G. F. Joplin, D. H. Carr, and S. R. Bloom, “Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995),” Clinical Endocrinology, vol. 26, no. 1, pp. 85–95, 1987. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Ronchi, P. Epaminonda, V. Cappiello, P. Beck-Peccoz, and M. Arosio, “Effects of two different somatostatin analogs on glucose tolerance in acromegaly,” Journal of Endocrinological Investigation, vol. 25, no. 6, pp. 502–507, 2002. View at Publisher · View at Google Scholar
  10. M. Giusti, E. Ciccarelli, D. Dallabonzana et al., “Clinical results of long-term slow-release lanreotide treatment of acromegaly,” European Journal of Clinical Investigation, vol. 27, no. 4, pp. 277–284, 1997. View at Publisher · View at Google Scholar
  11. B. L. Koop, A. G. Harris, and S. Ezzat, “Effect of octreotide on glucose tolerance in acromegaly,” European Journal of Endocrinology, vol. 130, no. 6, pp. 581–586, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Wang, M. Shen, W. He et al., “The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly,” Endocrine Journal, vol. 63, no. 9, pp. 819–834, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. M. I. Harris, W. C. Hadden, W. C. Knowler, and P. H. Bennett, “International criteria for the diagnosis of diabetes and impaired glucose tolerance,” Diabetes Care, vol. 8, no. 6, pp. 562–567, 1985. View at Publisher · View at Google Scholar · View at Scopus
  14. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Matsuda and R. A. DeFronzo, “Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp,” Diabetes Care, vol. 22, no. 9, pp. 1462–1470, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Kuloglu, M. Berberoglu, A. Kansu et al., “Effect of interferon therapy on glucose metabolism in children with chronic hepatitis B,” The Turkish Journal of Pediatrics, vol. 52, no. 6, pp. 594–601, 2010. View at Google Scholar
  17. A. Mitrakou, D. Kelley, M. Mokan et al., “Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance,” The New England Journal of Medicine, vol. 326, no. 1, pp. 22–29, 1992. View at Publisher · View at Google Scholar · View at Scopus
  18. S. M. Haffner, H. Miettinen, S. P. Gaskill, and M. P. Stern, “Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans,” Diabetes, vol. 44, no. 12, pp. 1386–1391, 1995. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Alford, H. Beck-Nielsen, G. M. Ward, and J. E. Henriksen, “Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients,” Diabetologia, vol. 40, no. 12, pp. 1439–1448, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Retnakaran, S. Shen, A. J. Hanley, V. Vuksan, J. K. Hamilton, and B. Zinman, “Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test,” Obesity, vol. 16, no. 8, pp. 1901–1907, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Retnakaran, Y. Qi, M. I. Goran, and J. K. Hamilton, “Evaluation of proposed oral disposition index measures in relation to the actual disposition index,” Diabetic Medicine, vol. 26, no. 12, pp. 1198–1203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Stancakova, M. Javorsky, T. Kuulasmaa, S. M. Haffner, J. Kuusisto, and M. Laakso, “Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men,” Diabetes, vol. 58, no. 5, pp. 1212–1221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. M. Tai, “A mathematical model for the determination of total area under glucose tolerance and other metabolic curves,” Diabetes Care, vol. 17, no. 2, pp. 152–154, 1994. View at Publisher · View at Google Scholar · View at Scopus
  24. A. K. Annamalai, A. Webb, N. Kandasamy et al., “A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 3, pp. 1040–1050, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Morange, F. De Boisvilliers, P. Chanson et al., “Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide,” The Journal of Clinical Endocrinology & Metabolism, vol. 79, no. 1, pp. 145–151, 1994. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Mazziotti, I. Floriani, S. Bonadonna, V. Torri, P. Chanson, and A. Giustina, “Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 5, pp. 1500–1508, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Baldelli, C. Battista, F. Leonetti et al., “Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment,” Clinical Endocrinology, vol. 59, no. 4, pp. 492–499, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Colao, R. S. Auriemma, M. Galdiero et al., “Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study,” The Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 2, pp. 528–537, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Colao, R. S. Auriemma, S. Savastano et al., “Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 8, pp. 2907–2914, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. K. K. Y. Ho, A. B. Jenkins, S. M. Furler, M. Borkman, and D. J. Chisholm, “Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly,” Clinical Endocrinology, vol. 36, no. 3, pp. 271–279, 1992. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Ciresi, M. C. Amato, R. Pivonello et al., “The metabolic profile in active acromegaly is gender-specific,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 1, pp. E51–E59, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. K. McKeage, “Pasireotide in acromegaly: a review,” Drugs, vol. 75, no. 9, pp. 1039–1048, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Colao, M. D. Bronstein, P. Freda et al., “Pasireotide versus octreotide in acromegaly: a head-to-head superiority study,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 3, pp. 791–799, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Urbani, C. Sardella, A. Calevro et al., “Effects of medical therapies for acromegaly on glucose metabolism,” European Journal of Endocrinology, vol. 169, no. 1, pp. 99–108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Steffin, B. Gutt, M. Bidlingmaier, C. Dieterle, F. Oltmann, and J. Schopohl, “Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly,” European Journal of Endocrinology, vol. 155, no. 1, pp. 73–78, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Giordano, A. Ciresi, M. C. Amato et al., “Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study,” Pituitary, vol. 15, no. 4, pp. 539–551, 2012. View at Publisher · View at Google Scholar · View at Scopus